P/E Ratio

Bio-Rad Laboratories trades at a price-to-earnings (P/E) ratio of 45.7x, meaning investors are paying $45.70 for every $1 of the company’s trailing earnings.

This valuation is nearly double the healthcare sector median of 24.6x, placing the stock in the 92nd percentile among sector peers—only a handful of competitors have a higher P/E. The year-over-year change is not available, but the quarter-over-quarter shift is a sharp increase of +357.5%, reflecting a dramatic move from the prior quarter’s 10.0x multiple. The combination of an elevated P/E and a sudden spike in the ratio suggests that earnings have likely fallen or the stock price has surged, creating a potential overvaluation risk if earnings do not recover quickly. This metric does not support the overall NEUTRAL verdict; a P/E at the 92nd percentile with a massive quarterly jump typically signals caution rather than a balanced outlook.

Frequently Asked Questions

Closest Sector Peers